Ohio Ozempic Vision Loss Lawsuits: Proving NAION Claims Against Novo Nordisk
Sudden darkness does not arrive with a warning. For many Ohio residents, the use of semaglutide medications like Ozempic and Wegovy has ended in a devastating diagnosis: Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). This is not a simple case of blurry vision that a new prescription can fix. This is an irreversible “stroke of the eye” that results in permanent partial or complete blindness.
If you are facing this crisis, you are not just a medical statistic. You are a victim of what we examine as a massive failure by a multi-billion dollar drug manufacturer to prioritize patient safety over marketing success. At Attorney911, we believe that when a company like Novo Nordisk knows—or should know—that their product can cause permanent blindness, they have a legal and moral duty to tell the truth to every doctor and patient in Ohio.
Understanding the Link Between Semaglutide and NAION
The medical community has begun to sound the alarm on a disturbing connection between semaglutide (the active ingredient in Ozempic and Wegovy) and NAION. While these drugs were originally designed to treat Type 2 diabetes, their surge in popularity for weight loss has exposed a much larger population to potential ocular risks.
Recent scientific findings have established a statistically significant relationship that Novo Nordisk has struggled to dismiss:
- The JAMA Ophthalmology Findings: A 2025 study examined patients who developed severe optic nerve disorders shortly after starting GLP-1 medications.
- The Harvard Research: Data from the Mass Eye and Ear Institute revealed that diabetic users of semaglutide were four times more likely to develop NAION.
- The Weight Loss Risk: Perhaps most shocking is that non-diabetic users taking the drug for weight loss faced a sevenfold increased risk of permanent vision loss.
NAION occurs when the blood flow to the optic nerve is compromised, causing the nerve to swell and eventually die. Because the optic nerve is the cable that carries visual information from the eye to the brain, once it is damaged, the loss of sight is permanent. We examine these cases through the lens of products liability, focusing on why the manufacturer downplayed these risks while aggressively promoting the drug.
Novo Nordisk’s Duty and the Ohio Product Liability Act (OPLA)
In Ohio, our legal framework is governed by the Ohio Product Liability Act (OPLA), found in the Ohio Revised Code §§ 2307.71 through 2307.80. Under this law, a manufacturer is strictly liable if their product’s warning is inadequate.
We focus our investigation on three central theories of liability:
- Failure to Warn: Despite emerging evidence of the risk of permanent blindness, Novo Nordisk did not include a warning for NAION on the Ozempic or Wegovy labels.
- Design Defect: We examine whether the drug’s mechanism of action—the way GLP-1 receptor agonists work in the body—inherently causes vascular changes that cut off the blood supply to the optic nerve.
- Negligence: We investigate whether the manufacturer failed to conduct proper post-marketing surveillance and clinical trials focused on eye health, even as reports of “sudden blindness” began to surface.
The pharmaceutical company will likely rely on the “learned intermediary” doctrine, arguing that their only duty was to warn your prescribing physician. However, that defense fails when the information provided to the doctor is incomplete or misleading. Our job is to prove that no physician could have properly weighed the risks because the manufacturer withheld the necessary data.
The “Changes Being Effected” (CBE) Rule: No Excuse for Silence
One of the most powerful tools we use in defective drug cases is a federal regulation known as the “Changes Being Effected” (CBE) rule under 21 CFR Part 201. Drug companies often try to hide behind the FDA, claiming they weren’t allowed to change their label.
This is a lie. The CBE regulation specifically allows a manufacturer to add or strengthen a warning on a label before getting FDA approval if they have “newly acquired information” about a serious risk. Novo Nordisk had the scientific data. They had the reports of blindness. They had the legal mechanism to add a warning to the Ozempic box. They chose to stay silent to protect their market share.
The 72-Hour Evidence Roadmap: Protecting Your Ohio Claim
In a mass tort case against a global giant, the first 72 hours after you realize you have an injury are the most important. The pharmaceutical company’s lawyers are already working to build a defense; we work until the evidence is frozen to protect you.
- Preserve the Records: Every prescription bottle, every box insert, and every pharmacy receipt is a piece of evidence. These show exactly what warning (or lack thereof) you were given.
- Secure Ophthalmic Scans: Diagnostic proof of NAION lives in Optical Coherence Tomography (OCT) and visual field tests. We work to ensure baseline and post-injury scans are secured before a hospital’s routine purge cycle.
- Subpoena Physician Detail Notes: We want to know exactly what the Novo Nordisk sales representatives told your doctor. Did they mention the risk of vision loss, or did they only focus on the drug’s effectiveness for weight loss?
- Litigation Holds: The day you call us, the preservation letter goes out. We demand a freeze on corporate internal communications to see if their own safety databases were flagging ocular risks long before the first Ohio lawsuit was filed.
What an Ozempic Vision Loss Case is Worth in Ohio
A diagnosis of NAION is life-altering. It can mean the end of a career, the loss of independence, and a profound change in your quality of life. In Ohio, we categorize these as catastrophic permanent injuries.
- Economic Damages: This includes your past and future medical costs for specialized eye care, assistive technology for the blind, and the total loss of your earning capacity if you can no longer work.
- Non-Economic Damages: Ohio law typically caps non-economic damages (pain and suffering), but those caps can be exceeded in cases of permanent, life-altering disabilities like the loss of sight. We fight for the full measure of your loss of quality of life and emotional distress.
- Punitive Damages: If discovery reveals that the manufacturer purposefully withheld safety data from the public to keep profits high, we may seek damages designed specifically to punish that corporate choice.
Based on the severity of vision loss—whether in one eye or both—and the age of the victim, these cases are being valued in the range of $500,000 to $5,000,000 or more. Past results depend on the facts of each case and do not guarantee future outcomes.
The Insurance and Pharma Playbook: How They Fight Back
Novo Nordisk and its insurers use a specific set of moves to devalue your claim. We know them because we’ve seen them hundreds of times.
- The “Pre-Existing” Defense: They will comb through your medical history to find any sign of Type 2 diabetes, high blood pressure, or vascular issues. They will try to argue that your vision loss was “inevitable” and had nothing to do with Ozempic. We counter this with the specific timing of your semaglutide usage and the 7x risk multiple identified by Harvard.
- The “Learned Intermediary” Wall: They will claim they told your doctor everything they were required to. We break this wall by proving the “safety information” they provided was intentionally diluted by their marketing materials.
- The Delay Tactic: Pharma companies try to wait until the statute of limitations runs out. In Ohio, you generally have two years from the date of your injury to file a personal injury claim under R.C. 2305.10. If you wait for the “official” recall, you may already be too late.
Why Experience Matters in Your Fight Against Novo Nordisk
When you take on a multi-billion-dollar corporation, you need a team that knows the pharmaceutical industry from the inside. Attorney Lupe Pena is a former insurance-defense lawyer who sat in the very rooms where claims like yours are priced. He knows the software they use to lowball victims and the delay tactics they use to exhaust families. Today, he uses that knowledge to fight for you.
Attorney Ralph Manginello has spent more than 27 years licensed in state and federal courtrooms. He is a competitor who hates to lose and has spent his career holding negligent companies accountable for catastrophic injuries.
We handle these cases on a contingency fee basis. This means we don’t get paid unless we win your case. Our fee is 33.33% if we settle before trial and 40% if we have to go to trial. We provide a free consultation 24/7 to help you understand your options.
Frequently Asked Questions
What is NAION?
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a medical condition where blood flow to the optic nerve is suddenly interrupted. It is often called a “stroke of the eye” and results in permanent, irreversible vision loss.
Can I get a settlement if Ozempic caused my blindness?
If it can be proven that the drug caused your vision loss and that the manufacturer failed to provide an adequate warning of that risk, you may be entitled to a significant recovery for medical bills, lost wages, and pain and suffering. How do contingency fees work?
Is there an Ozempic recall for vision loss?
As of mid-2026, there has not been a total recall of Ozempic for NAION, but the FDA has been monitoring the reports, and many lawsuits have been filed in Ohio and nationwide alleging the labels are defective for failing to include this warning.
What is the statute of limitations for an Ozempic lawsuit in Ohio?
In Ohio, the statute of limitations for personal injury claims is generally two years from the date of the injury (R.C. 2305.10). In the case of a defective drug, the clock usually starts when you discovered—or should have discovered—the link between the drug and your vision loss.
Do I have a case if I took Ozempic for weight loss?
Yes. In fact, research from Harvard indicates that non-diabetic users taking semaglutide for weight loss may have a sevenfold increased risk of developing NAION, which is even higher than the risk for diabetic users.
Can I sue the doctor who prescribed me Ozempic?
While it is possible to sue a doctor for medical malpractice if they ignored a known contraindication, most current Ozempic lawsuits target the manufacturer, Novo Nordisk. This is because the manufacturer held the safety data and failed to provide the doctor with the information needed to give a proper warning.
Is NAION the same as diabetic retinopathy?
No. Diabetic retinopathy is a gradual complication of diabetes that damages blood vessels in the retina. NAION is a sudden, localized loss of blood flow to the optic nerve. Many Ozempic victims were told their vision loss was just their diabetes progressing, when it was actually a drug-induced injury.
What should I do if I am experiencing vision changes on Ozempic?
You should seek immediate medical attention from an ophthalmologist and ask for an OCT scan and a visual field test. If you are diagnosed with NAION or optic nerve swelling, contact a lawyer immediately to preserve your rights.
Contact Our Ohio Ozempic Eye Injury Team Today
The pharmaceutical industry counts on victims feeling overwhelmed and alone. They count on you believing that your vision loss was just “bad luck.” It wasn’t.
We serve families across Ohio and nationwide in English and in Spanish. Hablamos Español. Our staff is available 24/7 to take your call and start the process of freezing the evidence. If you or a loved one has suffered permanent vision loss after using Ozempic or Wegovy, call 1-888-ATTY-911 for a free, confidential consultation. You don’t have to work through this alone. We work until the truth is on the record and the manufacturer is held to the standard the law demands.
1-888-ATTY-911
Legal Emergency Lawyers™
